Results 171 to 180 of about 6,040 (212)

Rimonabant and Depression

Pharmacopsychiatry, 2008
openaire   +2 more sources

Rimonabant Sanofi-Synthélabo.

Current opinion in investigational drugs (London, England : 2000), 2004
Rimonabant, an antagonist of central cannabinoid type 1 (CB1) receptors, is being developed by Sanofi-Synthélabo for the potential treatment of obesity and as a potential smoking cessation agent. Phase III trials were initiated for obesity in August 2001 and were ongoing in September 2003.
Jose R, Fernandez, David B, Allison
openaire   +1 more source

Depression and anxiety with rimonabant

The Lancet, 2007
Philip B, Mitchell, Margaret J, Morris
openaire   +2 more sources

The Hope and Fear of Rimonabant

JAMA, 2008
John S, Rumsfeld, Brahmajee K, Nallamothu   +1 more
openaire   +2 more sources

Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice

Arteriosclerosis, Thrombosis, and Vascular Biology, 2009
Réjane Paumelle, Virgile Visentin, Nathalie Hennuyer   +2 more
exaly  

Rimonabant

Reactions Weekly, 2013
openaire   +1 more source

Rimonabant Hydrochloride

Drugs of the Future, 2005
null Sorbera, L.A., null Castaner, J., null Silvestre, J.S.   +2 more
openaire   +1 more source

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

Lancet, The, 2006
André J Scheen, N Finer, Priscilla Hollander   +2 more
exaly  

Effect of Rimonabant on the High-Triglyceride/ Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat

Arteriosclerosis, Thrombosis, and Vascular Biology, 2009
Jean-Pierre Despres, Robert Ross, Natalie Almeras   +2 more
exaly  

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

Lancet, The, 2007
Robin Christensen, Henning Bliddal, Arne Astrup   +2 more
exaly